Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Arcutis Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-dermatologic diseases. The company operates within the biotechnology and specialty pharmaceuticals industries, with a strategic emphasis on inflammatory skin conditions that have significant unmet medical need. Its business model centers on the discovery, clinical development, regulatory approval, and commercialization of targeted topical therapies.
Arcutis’ primary revenue driver is ZORYVE® (roflumilast), a non-steroidal, topical phosphodiesterase-4 (PDE4) inhibitor approved in multiple formulations for chronic inflammatory dermatologic conditions. The company targets both dermatologists and patients seeking alternatives to topical steroids. Founded in 2016, Arcutis evolved from a development-stage company into a commercial organization following U.S. Food and Drug Administration approvals beginning in 2022, establishing its presence in the U.S. dermatology market.
Business Operations
Arcutis operates as a single-reportable segment biopharmaceutical company, generating revenue primarily from U.S. sales of ZORYVE® cream and ZORYVE® foam. These products are approved for indications including plaque psoriasis, atopic dermatitis, and seborrheic dermatitis, depending on formulation and patient population. Commercial operations include sales, marketing, medical affairs, and distribution, supported by third-party manufacturers.
The company’s activities are predominantly domestic, with commercialization focused on the United States. Arcutis controls its intellectual property portfolio related to roflumilast formulations and delivery technologies. Manufacturing is outsourced to contract manufacturing organizations, while the company maintains internal capabilities in clinical development, regulatory affairs, and commercialization. No material joint ventures have been disclosed in public filings.
Strategic Position & Investments
Arcutis’ strategy centers on maximizing the lifecycle value of roflumilast through additional formulations, new indications, and expanded patient populations. Growth initiatives emphasize increasing market penetration in dermatology by positioning ZORYVE® as a differentiated, steroid-free topical therapy with favorable efficacy and safety characteristics.
The company has prioritized internal research and development over acquisitions, and no major corporate acquisitions have been reported in public disclosures. Pipeline investment outside roflumilast has been limited, and certain earlier-stage dermatology programs were discontinued; further details on non-roflumilast assets are limited, and data inconclusive based on available public sources. Arcutis’ strategic focus remains tightly aligned with inflammatory dermatology rather than diversification into unrelated therapeutic areas.
Geographic Footprint
Arcutis is headquartered in Westlake Village, California, and its operational footprint is primarily concentrated in North America. Commercial activities, regulatory approvals, and revenue generation are currently focused on the United States market.
While the company has indicated interest in potential international expansion, it does not yet report material revenue from Europe, Asia-Pacific, or other global regions. International operations are limited and largely relate to clinical research activities and regulatory planning rather than established commercial infrastructure.
Leadership & Governance
Arcutis was founded by experienced biotechnology executives with backgrounds in dermatology drug development. The leadership team emphasizes scientific rigor, disciplined capital allocation, and a focused commercial strategy aimed at building a leading dermatology franchise around differentiated topical therapies.
Key executives include:
- Frank Watanabe – President and Chief Executive Officer
- Larry Sullivan – Chief Financial Officer
- Patrick Burnett – Chief Medical Officer
The company is publicly traded and governed by a board of directors with experience across biotechnology, pharmaceuticals, and corporate finance, supporting oversight of long-term strategy and shareholder interests.